Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Datroway extends survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy, per phase III trial.
AstraZeneca and Daiichi Sankyo announced that Datroway significantly improved overall and progression-free survival in patients with metastatic triple-negative breast cancer who aren’t eligible for immunotherapy, based on phase III trial results.
It is the first treatment to show a survival benefit over chemotherapy in this group, which includes about 70% of patients.
The drug’s safety profile remained consistent, and the companies plan to submit data to regulators and present findings at a medical meeting.
Datroway, a Trop2-directed antibody-drug conjugate, is already approved for some lung cancers.
5 Articles
Datroway extiende la supervivencia en pacientes con cáncer de mama triple negativo metastásico no elegibles para inmunoterapia, según ensayos de fase III.